We seek to make a big difference in genetic disorders. At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most.
in 2022 FY Total Revenues
Manufacturing, R&D, Regulatory, and Commercial
"Core 4" Product Framework
Genetic, Targeted, Assessable, Transformational
The 2023 Annual Meeting of Stockholders of BioMarin Pharmaceutical Inc. will be held on Tuesday, May 23, 2023 at 10:00 a.m. (Pacific Time).
We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
Our executive team is made up of tech leaders with diverse backgrounds and a singular focus.
Media & Press
Sign up for alerts to receive updates on company announcements, financial information and more!